FAWAZ FAISAL: Open Payments
NPI 1487679361 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 39 payments from 13 companies in 2025. Trend: 2023 $889 · 2024 $1,443 · 2025 $947
Food & beverage: $947
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $179 |
| Inspire Medical Systems, Inc. | 5 | $143 |
| Biogen, Inc. | 5 | $124 |
| SK Life Science, Inc. | 1 | $123 |
| Novartis Pharmaceuticals Corporation | 4 | $115 |
| Lilly USA, LLC | 2 | $58 |
| ARGENX US, INC. | 2 | $51 |
| JAZZ PHARMACEUTICALS INC. | 2 | $33 |
| Genentech USA, Inc. | 1 | $32 |
| LivaNova USA, Inc. | 1 | $28 |
Products named: QULIPTA, INSPIRE, XCOPRI, KESIMPTA, VUMERITY, VYVGART, ZEPBOUND, XYWAV.
Industry payments across CA — which companies pay providers there.
